1
|
Cuoghi IC, da Silva Soares MF, dos Santos GMC, dos-Reis FJC, Poli-Neto OB, de Andrade JM, Bosquesi PL, Orlandini LF, Tiezzi DG. 10-year opportunistic mammographic screening scenario in Brazil and its impact on breast cancer early detection: a nationwide population-based study. J Glob Health 2022; 12:04061. [PMID: 36227588 PMCID: PMC9564571 DOI: 10.7189/jogh.12.04061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Background Methods Results Conclusions
Collapse
Affiliation(s)
- Isabela Campeti Cuoghi
- CEPAM – Centro de Pesquisa Avançada em Medicina da UNILAGO, Faculdade de Medicina UNILAGO, União das Faculdades dos Grandes Lagos, São José do Rio Preto, São Paulo, Brazil
| | - Mariana Furlani da Silva Soares
- CEPAM – Centro de Pesquisa Avançada em Medicina da UNILAGO, Faculdade de Medicina UNILAGO, União das Faculdades dos Grandes Lagos, São José do Rio Preto, São Paulo, Brazil
| | | | | | - Omero Benedicto Poli-Neto
- Faculdade de Medicina de Ribeirão Preto FMRP – USP, Ribeirão Preto, São Paulo, Brazil
- Laboratory for Translational Data Science - University of São Paulo, São Paulo, Brazil
| | | | - Priscila Longhin Bosquesi
- CEPAM – Centro de Pesquisa Avançada em Medicina da UNILAGO, Faculdade de Medicina UNILAGO, União das Faculdades dos Grandes Lagos, São José do Rio Preto, São Paulo, Brazil
- Faculdade de Ciências Farmacêuticas UNESP, Araraquara, São Paulo, Brazil
| | | | - Daniel Guimarães Tiezzi
- CEPAM – Centro de Pesquisa Avançada em Medicina da UNILAGO, Faculdade de Medicina UNILAGO, União das Faculdades dos Grandes Lagos, São José do Rio Preto, São Paulo, Brazil
- Faculdade de Medicina de Ribeirão Preto FMRP – USP, Ribeirão Preto, São Paulo, Brazil
- Laboratory for Translational Data Science - University of São Paulo, São Paulo, Brazil
| |
Collapse
|
2
|
Orlandini LF, Antonio MVDN, Espreafico CR, Bosquesi PL, Poli-Neto OB, de Andrade JM, Dos Reis FJC, Tiezzi DG. Epidemiological Analyses Reveal a High Incidence of Breast Cancer in Young Women in Brazil. JCO Glob Oncol 2021; 7:81-88. [PMID: 33434069 PMCID: PMC8081493 DOI: 10.1200/go.20.00440] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
PURPOSE Breast cancer screening is not recommended for young women (< 40 years old); therefore, those diagnosed are more likely to have advanced and metastatic disease, reducing treatment outcomes. This study aimed to investigate breast cancer epidemiology among young women in Brazil. METHODS Data from three publicly available databases and a cohort from a university hospital in Brazil were analyzed in a retrospective study. Descriptive statistics was performed on disease prevalence and stage distribution across age groups. Incidence was estimated using age-standardized incidence ratio. The impact of age in disease-specific survival was also analyzed. RESULTS Invasive breast cancer prevalence data by age group revealed that 4.4% and 20.6% of patients were < 35 and < 45 years old, respectively. In the United States, this prevalence was 1.85% and 11.5%, respectively (odds ratio [OR], 2.2; P < .0001). The percentage of regional and metastatic diseases were higher in São Paulo State (Fundação Oncocentro de São Paulo [FOSP]) compared with the United States (45% and 9.8% v 29% and 5.7%, respectively; P < .0001). In FOSP, regional and metastatic disease prevalence were higher among young patients (53.5% and 11.3%, respectively). The median tumor size in patients < 40 years old was higher (25.0 mm × 20.9 mm; P < .0001), and young patients have higher risk to be diagnosed with positive lymph nodes (OR, 1.5; P = .004) and higher proportion of luminal-B and triple-negative (TNBC) tumors. Young patients have a poor disease-specific survival because of late-stage diagnosis and more aggressive breast cancer subtypes (human epidermal growth factor receptor 2-enriched and TNBC) (P < .0001). CONCLUSION In Brazil, breast cancer prevalence among young patients and late-stage incidence during this age span is higher. Advanced disease and more aggressive subtypes lead to a significant impact on breast cancer-specific survival in young patients.
Collapse
Affiliation(s)
- Leonardo Fleury Orlandini
- Ribeirão Preto School of Medicine, Department of Gynecology and Obstetrics, Gynecologic Oncology and Breast Disease Division, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
| | | | - Claiver Renato Espreafico
- Advanced Research Center in Medicine, Union of the Colleges of the Great Lakes (UNILAGO), São José do Rio Preto, São Paulo, Brazil
| | - Priscila Longhin Bosquesi
- Advanced Research Center in Medicine, Union of the Colleges of the Great Lakes (UNILAGO), São José do Rio Preto, São Paulo, Brazil
| | - Omero Benedito Poli-Neto
- Ribeirão Preto School of Medicine, Department of Gynecology and Obstetrics, Gynecologic Oncology and Breast Disease Division, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - Jurandyr Moreira de Andrade
- Ribeirão Preto School of Medicine, Department of Gynecology and Obstetrics, Gynecologic Oncology and Breast Disease Division, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - Francisco José Cândido Dos Reis
- Ribeirão Preto School of Medicine, Department of Gynecology and Obstetrics, Gynecologic Oncology and Breast Disease Division, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - Daniel Guimarães Tiezzi
- Ribeirão Preto School of Medicine, Department of Gynecology and Obstetrics, Gynecologic Oncology and Breast Disease Division, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.,Advanced Research Center in Medicine, Union of the Colleges of the Great Lakes (UNILAGO), São José do Rio Preto, São Paulo, Brazil
| |
Collapse
|
3
|
Bosquesi PL, Melchior ACB, Pavan AR, Lanaro C, de Souza CM, Rusinova R, Chelucci RC, Barbieri KP, Fernandes GFDS, Carlos IZ, Andersen OS, Costa FF, Dos Santos JL. Synthesis and evaluation of resveratrol derivatives as fetal hemoglobin inducers. Bioorg Chem 2020; 100:103948. [PMID: 32450391 PMCID: PMC8052979 DOI: 10.1016/j.bioorg.2020.103948] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2020] [Revised: 05/12/2020] [Accepted: 05/14/2020] [Indexed: 12/29/2022]
Abstract
Resveratrol (RVT) derivatives (10a-i) were designed, synthesized, and evaluated for their potential as gamma-globin inducers in treating Sickle Cell Disease (SCD) symptoms. All compounds were able to release NO at different levels ranging from 0 to 26.3%, while RVT did not demonstrate this effect. In vivo, the antinociceptive effect was characterized using an acetic acid-induced abdominal contortion model. All compounds exhibited different levels of protection, ranging from 5.9 to 37.3%; the compound 10a was the most potent among the series. At concentrations between 3.13 and 12.5 µM, the derivative 10a resulted in a reduction of 41.1-64.3% in the TNF-α levels in the supernatants of macrophages that were previously LPS-stimulated. This inhibitory effect was higher than that of RVT used as the control. In addition, the compound 10a and RVT induced double the production of the gamma-globin chains (γG + γA), compared to the vehicle, using CD34+ cells. Compound 10a also did not induce membrane perturbation and it was not mutagenic in the in vivo assay. Thus, compound 10a emerged as a new prototype of the gamma-globin-inducer group with additional analgesic and anti-inflammatory activities and proving to be a useful alternative to treat SCD symptoms.
Collapse
Affiliation(s)
| | | | - Aline Renata Pavan
- São Paulo State University (UNESP), School of Pharmaceutical Sciences, Araraquara 14800-903, Brazil
| | - Carolina Lanaro
- University of Campinas (UNICAMP), Hematology and Hemotherapy Center, Campinas 13083-878, Brazil
| | | | - Radda Rusinova
- Weill Cornell Medical College, Department of Physiology and Biophysics, New York, NY 10065-489, United States
| | - Rafael Consolin Chelucci
- São Paulo State University (UNESP), School of Pharmaceutical Sciences, Araraquara 14800-903, Brazil
| | - Karina Pereira Barbieri
- São Paulo State University (UNESP), School of Pharmaceutical Sciences, Araraquara 14800-903, Brazil
| | | | - Iracilda Zepone Carlos
- São Paulo State University (UNESP), School of Pharmaceutical Sciences, Araraquara 14800-903, Brazil
| | - Olaf Sparre Andersen
- Weill Cornell Medical College, Department of Physiology and Biophysics, New York, NY 10065-489, United States
| | - Fernando Ferreira Costa
- University of Campinas (UNICAMP), Hematology and Hemotherapy Center, Campinas 13083-878, Brazil
| | - Jean Leandro Dos Santos
- São Paulo State University (UNESP), School of Pharmaceutical Sciences, Araraquara 14800-903, Brazil.
| |
Collapse
|
4
|
Dos Santos Fernandes GF, de Souza PC, Moreno-Viguri E, Santivañez-Veliz M, Paucar R, Pérez-Silanes S, Chegaev K, Guglielmo S, Lazzarato L, Fruttero R, Man Chin C, da Silva PB, Chorilli M, Solcia MC, Ribeiro CM, Silva CSP, Marino LB, Bosquesi PL, Hunt DM, de Carvalho LPS, de Souza Costa CA, Cho SH, Wang Y, Franzblau SG, Pavan FR, Dos Santos JL. Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity. J Med Chem 2017; 60:8647-8660. [PMID: 28968083 PMCID: PMC5677254 DOI: 10.1021/acs.jmedchem.7b01332] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
![]()
Tuberculosis,
caused by Mycobacterium tuberculosis (Mtb), is the infectious disease responsible for
the highest number of deaths worldwide. Herein, 22 new N-oxide-containing
compounds were synthesized followed by in vitro and in vivo evaluation of their antitubercular potential against Mtb. Compound 8 was found to be the most promising
compound, with MIC90 values of 1.10 and 6.62 μM against
active and nonreplicating Mtb, respectively. Additionally,
we carried out in vivo experiments to confirm the
safety and efficacy of compound 8; the compound was found
to be orally bioavailable and highly effective, leading to a reduction
of Mtb to undetectable levels in a mouse model of
infection. Microarray-based initial studies on the mechanism of action
suggest that compound 8 blocks translation.
Altogether, these results indicate that benzofuroxan derivative 8 is a promising lead compound for the development of a novel
chemical class of antitubercular drugs.
Collapse
Affiliation(s)
- Guilherme Felipe Dos Santos Fernandes
- São Paulo State University (UNESP) , Institute of Chemistry, Araraquara 14800060, Brazil.,São Paulo State University (UNESP) , School of Pharmaceutical Sciences, Araraquara 14800903, Brazil.,Universidad de Navarra , Department of Organic and Pharmaceutical Chemistry, Instituto de Salud Tropical, Pamplona 31008, Spain
| | - Paula Carolina de Souza
- São Paulo State University (UNESP) , School of Pharmaceutical Sciences, Araraquara 14800903, Brazil.,Institute of Tuberculosis Research, University of Illinois at Chicago , Chicago, Illinois 60607, United States
| | - Elsa Moreno-Viguri
- Universidad de Navarra , Department of Organic and Pharmaceutical Chemistry, Instituto de Salud Tropical, Pamplona 31008, Spain
| | - Mery Santivañez-Veliz
- Universidad de Navarra , Department of Organic and Pharmaceutical Chemistry, Instituto de Salud Tropical, Pamplona 31008, Spain
| | - Rocio Paucar
- Universidad de Navarra , Department of Organic and Pharmaceutical Chemistry, Instituto de Salud Tropical, Pamplona 31008, Spain
| | - Silvia Pérez-Silanes
- Universidad de Navarra , Department of Organic and Pharmaceutical Chemistry, Instituto de Salud Tropical, Pamplona 31008, Spain
| | - Konstantin Chegaev
- Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino , Turin 10124, Italy
| | - Stefano Guglielmo
- Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino , Turin 10124, Italy
| | - Loretta Lazzarato
- Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino , Turin 10124, Italy
| | - Roberta Fruttero
- Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino , Turin 10124, Italy
| | - Chung Man Chin
- São Paulo State University (UNESP) , School of Pharmaceutical Sciences, Araraquara 14800903, Brazil
| | - Patricia Bento da Silva
- São Paulo State University (UNESP) , School of Pharmaceutical Sciences, Araraquara 14800903, Brazil
| | - Marlus Chorilli
- São Paulo State University (UNESP) , School of Pharmaceutical Sciences, Araraquara 14800903, Brazil
| | - Mariana Cristina Solcia
- São Paulo State University (UNESP) , School of Pharmaceutical Sciences, Araraquara 14800903, Brazil
| | - Camila Maríngolo Ribeiro
- São Paulo State University (UNESP) , School of Pharmaceutical Sciences, Araraquara 14800903, Brazil
| | - Caio Sander Paiva Silva
- São Paulo State University (UNESP) , School of Pharmaceutical Sciences, Araraquara 14800903, Brazil
| | | | | | - Debbie M Hunt
- Mycobacterial Metabolism and Antibiotic Research Laboratory, The Francis Crick Institute , 1 Midland Road, London NW1 1AT, United Kingdom
| | - Luiz Pedro S de Carvalho
- Mycobacterial Metabolism and Antibiotic Research Laboratory, The Francis Crick Institute , 1 Midland Road, London NW1 1AT, United Kingdom
| | | | - Sang Hyun Cho
- Institute of Tuberculosis Research, University of Illinois at Chicago , Chicago, Illinois 60607, United States
| | - Yuehong Wang
- Institute of Tuberculosis Research, University of Illinois at Chicago , Chicago, Illinois 60607, United States
| | - Scott Gary Franzblau
- Institute of Tuberculosis Research, University of Illinois at Chicago , Chicago, Illinois 60607, United States
| | - Fernando Rogério Pavan
- São Paulo State University (UNESP) , School of Pharmaceutical Sciences, Araraquara 14800903, Brazil
| | - Jean Leandro Dos Santos
- São Paulo State University (UNESP) , Institute of Chemistry, Araraquara 14800060, Brazil.,São Paulo State University (UNESP) , School of Pharmaceutical Sciences, Araraquara 14800903, Brazil
| |
Collapse
|
5
|
Chelucci RC, Dutra LA, Lopes Pires ME, de Melo TRF, Bosquesi PL, Chung MC, Dos Santos JL. Antiplatelet and antithrombotic activities of non-steroidal anti-inflammatory drugs containing an N-acyl hydrazone subunit. Molecules 2014; 19:2089-99. [PMID: 24549233 PMCID: PMC6270978 DOI: 10.3390/molecules19022089] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2013] [Revised: 01/30/2014] [Accepted: 02/10/2014] [Indexed: 02/02/2023] Open
Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) 1–5 containing an N-acyl hydrazone subunit were prepared and their antiplatelet and antithrombotic activities assessed in vitro and in vivo. Compounds 1–5 inhibited the platelet aggregation induced by adenosine diphosphate and/or arachidonic acid, with inhibition rates of 18.0%–61.1% and 65.9%–87.3%, respectively. Compounds 1 and 5 were the most active compounds, inhibiting adenosine-diphosphate-induced platelet aggregation by 57.2% and 61.1%, respectively. The inhibitory rates for arachidonic-acid-induced platelet aggregation were similar for compound 2 (80.8%) and acetylsalicylic acid (ASA, 80%). After their oral administration to mice, compounds 1, 3, and 5 showed shorter mean bleeding times than ASA. Compounds 1 and 5 also protected against thromboembolic events, with survival rates of 40% and 33%, respectively, compared with 30% for ASA. In conclusion, these results indicate that these novel NSAIDs containing an NAH subunit may offer better antiplatelet and antithrombotic activities than ASA.
Collapse
Affiliation(s)
- Rafael Consolin Chelucci
- Departamento de Fármacos e Medicamentos, Faculdade de Ciências Farmacêuticas-UNESP, Rodovia Araraquara Jaú Km, Araraquara, SP, 01, 14801-902, Brazil.
| | - Luiz Antônio Dutra
- Departamento de Fármacos e Medicamentos, Faculdade de Ciências Farmacêuticas-UNESP, Rodovia Araraquara Jaú Km, Araraquara, SP, 01, 14801-902, Brazil.
| | - Maria Elisa Lopes Pires
- Departamento de Fármacos e Medicamentos, Faculdade de Ciências Farmacêuticas-UNESP, Rodovia Araraquara Jaú Km, Araraquara, SP, 01, 14801-902, Brazil.
| | - Thais Regina Ferreira de Melo
- Departamento de Fármacos e Medicamentos, Faculdade de Ciências Farmacêuticas-UNESP, Rodovia Araraquara Jaú Km, Araraquara, SP, 01, 14801-902, Brazil.
| | - Priscila Longhin Bosquesi
- Departamento de Fármacos e Medicamentos, Faculdade de Ciências Farmacêuticas-UNESP, Rodovia Araraquara Jaú Km, Araraquara, SP, 01, 14801-902, Brazil.
| | - Man Chin Chung
- Departamento de Fármacos e Medicamentos, Faculdade de Ciências Farmacêuticas-UNESP, Rodovia Araraquara Jaú Km, Araraquara, SP, 01, 14801-902, Brazil.
| | - Jean Leandro Dos Santos
- Departamento de Fármacos e Medicamentos, Faculdade de Ciências Farmacêuticas-UNESP, Rodovia Araraquara Jaú Km, Araraquara, SP, 01, 14801-902, Brazil.
| |
Collapse
|
6
|
Blau L, Menegon RF, Trossini GH, Molino JVD, Vital DG, Cicarelli RMB, Passerini GD, Bosquesi PL, Chin CM. Design, synthesis and biological evaluation of new aryl thiosemicarbazone as antichagasic candidates. Eur J Med Chem 2013; 67:142-51. [DOI: 10.1016/j.ejmech.2013.04.022] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2013] [Revised: 03/29/2013] [Accepted: 04/08/2013] [Indexed: 10/26/2022]
|
7
|
dos Santos JL, Moreira V, Campos ML, Chelucci RC, Barbieri KP, de Castro Souto PCM, Matsubara MH, Teixeira C, Bosquesi PL, Peccinini RG, Chin CM. Pharmacological evaluation and preliminary pharmacokinetics studies of a new diclofenac prodrug without gastric ulceration effect. Int J Mol Sci 2012. [PMID: 23203127 PMCID: PMC3509643 DOI: 10.3390/ijms131115305] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Long-term nonsteroidal anti-inflammatory drugs (NSAIDs) therapy has been associated with several adverse effects such as gastric ulceration and cardiovascular events. Among the molecular modifications strategies, the prodrug approach is a useful tool to discover new safe NSAIDs. The 1-(2,6-dichlorophenyl)indolin-2-one is a diclofenac prodrug which demonstrated relevant anti-inflammatory properties without gastro ulceration effect. In addition, the prodrug decreases PGE(2) levels, COX-2 expression and cellular influx into peritoneal cavity induced by carrageenan treatment. Preliminary pharmacokinetic studies have shown in vivo bioconversion of prodrug to diclofenac. This prodrug is a new nonulcerogenic NSAID useful to treat inflammatory events by long-term therapy.
Collapse
Affiliation(s)
- Jean Leandro dos Santos
- Lapdesf—Laboratory of Research and Drug Development, Drugs and Medicines Department, School of Pharmaceutical Science—UNESP Rodovia Araraquara Jaú Km. 01, 14801-902, Araraquara, SP, Brazil; E-Mails: (R.C.C.); (K.P.B.); (P.L.B.)
- Authors to whom correspondence should be addressed; E-Mails: (J.L.S.); (C.M.C.); Tel.: +55-16-3301-6972 (C.M.C.); Fax: +55-16-3301-6962 (J.L.S.)
| | - Vanessa Moreira
- Pharmacology Laboratory, Inflammation unit, Butantan Institute, Vital Brazil Avenue 1500, 05503-900, São Paulo, Brazil; E-Mails: (V.M.); (P.C.M.C.S.); (M.H.M.); (C.T.)
| | - Michel Leandro Campos
- Natural Active Principles and Toxicology Department, School of Pharmaceutical Science—UNESP Rodovia Araraquara Jaú Km. 01, 14801-902, Araraquara, SP, Brazil; E-Mails: (M.L.C.); (R.G.P.)
| | - Rafael Consolin Chelucci
- Lapdesf—Laboratory of Research and Drug Development, Drugs and Medicines Department, School of Pharmaceutical Science—UNESP Rodovia Araraquara Jaú Km. 01, 14801-902, Araraquara, SP, Brazil; E-Mails: (R.C.C.); (K.P.B.); (P.L.B.)
| | - Karina Pereira Barbieri
- Lapdesf—Laboratory of Research and Drug Development, Drugs and Medicines Department, School of Pharmaceutical Science—UNESP Rodovia Araraquara Jaú Km. 01, 14801-902, Araraquara, SP, Brazil; E-Mails: (R.C.C.); (K.P.B.); (P.L.B.)
| | - Pollyana Cristina Maggio de Castro Souto
- Pharmacology Laboratory, Inflammation unit, Butantan Institute, Vital Brazil Avenue 1500, 05503-900, São Paulo, Brazil; E-Mails: (V.M.); (P.C.M.C.S.); (M.H.M.); (C.T.)
| | - Márcio Hideki Matsubara
- Pharmacology Laboratory, Inflammation unit, Butantan Institute, Vital Brazil Avenue 1500, 05503-900, São Paulo, Brazil; E-Mails: (V.M.); (P.C.M.C.S.); (M.H.M.); (C.T.)
| | - Catarina Teixeira
- Pharmacology Laboratory, Inflammation unit, Butantan Institute, Vital Brazil Avenue 1500, 05503-900, São Paulo, Brazil; E-Mails: (V.M.); (P.C.M.C.S.); (M.H.M.); (C.T.)
| | - Priscila Longhin Bosquesi
- Lapdesf—Laboratory of Research and Drug Development, Drugs and Medicines Department, School of Pharmaceutical Science—UNESP Rodovia Araraquara Jaú Km. 01, 14801-902, Araraquara, SP, Brazil; E-Mails: (R.C.C.); (K.P.B.); (P.L.B.)
| | - Rosângela Gonçalves Peccinini
- Natural Active Principles and Toxicology Department, School of Pharmaceutical Science—UNESP Rodovia Araraquara Jaú Km. 01, 14801-902, Araraquara, SP, Brazil; E-Mails: (M.L.C.); (R.G.P.)
| | - Chung Man Chin
- Lapdesf—Laboratory of Research and Drug Development, Drugs and Medicines Department, School of Pharmaceutical Science—UNESP Rodovia Araraquara Jaú Km. 01, 14801-902, Araraquara, SP, Brazil; E-Mails: (R.C.C.); (K.P.B.); (P.L.B.)
- Authors to whom correspondence should be addressed; E-Mails: (J.L.S.); (C.M.C.); Tel.: +55-16-3301-6972 (C.M.C.); Fax: +55-16-3301-6962 (J.L.S.)
| |
Collapse
|
8
|
Dos Santos JL, Lanaro C, Chelucci RC, Gambero S, Bosquesi PL, Reis JS, Lima LM, Cerecetto H, González M, Costa FF, Chung MC. Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms. part II: furoxan derivatives. J Med Chem 2012; 55:7583-92. [PMID: 22889416 DOI: 10.1021/jm300602n] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Phthalimide derivatives containing furoxanyl subunits as nitric oxide (NO)-donors (3a-g) were designed, synthesized, and evaluated in vitro and in vivo for their potential uses in the oral treatment of sickle cell disease symptoms. All compounds (3a-g) demonstrated NO-donor properties at different levels. Moreover, compounds 3b and 3c demonstrated analgesic activity. Compound 3b was determined to be a promising drug candidate for the aforementioned uses, and it was further evaluated in K562 culture cells to determine its ability to increase levels of γ-globin expression. After 96 h at 5 μM, compound 3b was able to induce γ-globin expression by nearly three times. Mutagenic studies using micronucleus tests in peripheral blood cells of mice demonstrated that compound 3b reduces the mutagenic profile as compared with hydroxyurea. Compound 3b has emerged as a new leading drug candidate with multiple beneficial effects for the treatment of sickle cell disease symptoms and provides an alternative to hydroxyurea treatment.
Collapse
Affiliation(s)
- Jean Leandro Dos Santos
- Lapdesf-Laboratório de Pesquisa e Desenvolvimento de Fármacos, Departamento de Fármacos e Medicamentos, Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista-UNESP, Rodovia Araraquara Jaú Km. 01, 14801-902 Araraquara, SP, Brazil.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Chung MC, Bosquesi PL, dos Santos JL. A prodrug approach to improve the physico-chemical properties and decrease the genotoxicity of nitro compounds. Curr Pharm Des 2012; 17:3515-26. [PMID: 22074424 DOI: 10.2174/138161211798194512] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Revised: 07/26/2011] [Accepted: 08/24/2011] [Indexed: 11/22/2022]
Abstract
In therapeutics research, the nitro compounds are part of an important group of drugs with multiple pharmacological activities. However, in drug design, the inclusion of a nitro group in a molecule changes the physico-chemical and electronic properties and is associated with increased mutagenicity and carcinogenicity. In addition, several studies have related the relationship between the antimicrobial and/or anti-protozoal activity and the mutagenic effect to reduction of the nitro group. This work reviews the toxicity of nitro compounds and shows how the use of prodrugs can increase the biological activity and decrease the genotoxicity of nitro compounds, without any modification in nitro reduction behavior, but rather by physico-chemical improvement. Examples are given of metronidazole and nitrofurazone prodrugs.
Collapse
Affiliation(s)
- Man Chin Chung
- Lapdesf- Laboratory of Drug Desing, Dept of Drugs and Medicines, School of Pharmaceutical Sciences, University of São Paulo State, Rodovia Araraquara- Jaú km1, cep 14802-901, Araraquara, SP, Brazil.
| | | | | |
Collapse
|
10
|
Bosquesi PL, Melo TRF, Vizioli EO, Santos JLD, Chung MC. Anti-Inflammatory Drug Design Using a Molecular Hybridization Approach. Pharmaceuticals (Basel) 2011; 4:1450-1474. [PMID: 27721332 PMCID: PMC4060134 DOI: 10.3390/ph4111450] [Citation(s) in RCA: 55] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2011] [Revised: 10/20/2011] [Accepted: 10/20/2011] [Indexed: 12/21/2022] Open
Abstract
The design of new drugs with better physiochemical properties, adequate absorption, distribution, metabolism, and excretion, effective pharmacologic potency and lacking toxicity remains is a challenge. Inflammation is the initial trigger of several different diseases, such as Alzheimer's disease, asthma, atherosclerosis, colitis, rheumatoid arthritis, depression, cancer; and disorders such as obesity and sexual dysfunction. Although inflammation is not the direct cause of these disorders, inflammatory processes often increase related pain and suffering. New anti-inflammatory drugs developed using molecular hybridization techniques to obtain multiple-ligand drugs can act at one or multiple targets, allowing for synergic action and minimizing toxicity. This work is a review of new anti-inflammatory drugs developed using the molecular modification approach.
Collapse
Affiliation(s)
- Priscila Longhin Bosquesi
- Lapdesf, Laboratory of Drug Design, Department of Drugs and Medicines, School of Pharmaceutical Sciences, University of São Paulo State (UNESP), Rodovia Araraquara-Jaú, km 1, Araraquara, SP, Cep. 14.802-901, Brazil.
| | - Thais Regina Ferreira Melo
- Lapdesf, Laboratory of Drug Design, Department of Drugs and Medicines, School of Pharmaceutical Sciences, University of São Paulo State (UNESP), Rodovia Araraquara-Jaú, km 1, Araraquara, SP, Cep. 14.802-901, Brazil
| | - Ednir Oliveira Vizioli
- Lapdesf, Laboratory of Drug Design, Department of Drugs and Medicines, School of Pharmaceutical Sciences, University of São Paulo State (UNESP), Rodovia Araraquara-Jaú, km 1, Araraquara, SP, Cep. 14.802-901, Brazil.
| | - Jean Leandro Dos Santos
- Lapdesf, Laboratory of Drug Design, Department of Drugs and Medicines, School of Pharmaceutical Sciences, University of São Paulo State (UNESP), Rodovia Araraquara-Jaú, km 1, Araraquara, SP, Cep. 14.802-901, Brazil.
| | - Man Chin Chung
- Lapdesf, Laboratory of Drug Design, Department of Drugs and Medicines, School of Pharmaceutical Sciences, University of São Paulo State (UNESP), Rodovia Araraquara-Jaú, km 1, Araraquara, SP, Cep. 14.802-901, Brazil.
| |
Collapse
|
11
|
Dos Santos JL, Longhin Bosquesi P, Varanda EA, Moreira Lima L, Chung MC. Assessment of the in vivo genotoxicity of new lead compounds to treat sickle cell disease. Molecules 2011; 16:2982-9. [PMID: 21471937 PMCID: PMC6260610 DOI: 10.3390/molecules16042982] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2011] [Revised: 03/31/2011] [Accepted: 04/02/2011] [Indexed: 11/30/2022] Open
Abstract
The compounds 1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl nitrate (C1), (1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl nitrate (C2), 3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)benzyl nitrate (C3), 4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-N-hydroxy-benzenesulfonamide (C4), 4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)benzyl nitrate (C5), and 2-[4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)phenyl]ethyl nitrate (C6) were evaluated with a micronucleus test using mouse peripheral blood to identify new candidate drugs for the treatment of sickle cell disease (SCD) that are safer than hydroxyurea. The compounds induced an average frequency of micronucleated reticulocytes (MNRET) of less than six per 1,000 cells at 12.5, 25, 50, and 100 mg/kg, whereas hydroxyurea induced an average MNRET frequency of 7.8, 9.8, 15, and 33.7 per 1000 cells respectively, at the same concentrations. Compounds C1-C6 are new non-genotoxic in vivo candidate drugs for the treatment of SCD symptoms.
Collapse
Affiliation(s)
- Jean Leandro Dos Santos
- Laboratório de Pesquisa e Desenvolvimento de Fármacos (Lapdesf), Departamento de Fármacos e Medicamentos, Faculdade de Ciências Farmacêuticas, Univ Estadual Paulista (UNESP), Rodovia Araraquara Jaú Km. 01, 14801-902 Araraquara, SP, Brazil.
| | | | | | | | | |
Collapse
|
12
|
Chung MC, Ferreira EI, Santos JL, Giarolla J, Rando DG, Almeida AE, Bosquesi PL, Menegon RF, Blau L. Prodrugs for the treatment of neglected diseases. Molecules 2007; 13:616-77. [PMID: 18463559 PMCID: PMC6245083 DOI: 10.3390/molecules13030616] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2008] [Revised: 03/12/2008] [Accepted: 03/12/2008] [Indexed: 11/16/2022] Open
Abstract
Recently, World Health Organization (WHO) and Medicins San Frontieres (MSF) proposed a classification of diseases as global, neglected and extremely neglected. Global diseases, such as cancer, cardiovascular and mental (CNS) diseases represent the targets of the majority of the R&D efforts of pharmaceutical companies. Neglected diseases affect millions of people in the world yet existing drug therapy is limited and often inappropriate. Furthermore, extremely neglected diseases affect people living under miserable conditions who barely have access to the bare necessities for survival. Most of these diseases are excluded from the goals of the R&D programs in the pharmaceutical industry and therefore fall outside the pharmaceutical market. About 14 million people,mainly in developing countries, die each year from infectious diseases. From 1975 to 1999,1393 new drugs were approved yet only 1% were for the treatment of neglected diseases[3]. These numbers have not changed until now, so in those countries there is an urgent need for the design and synthesis of new drugs and in this area the prodrug approach is a very interesting field. It provides, among other effects, activity improvements and toxicity decreases for current and new drugs, improving market availability. It is worth noting that it is essential in drug design to save time and money, and prodrug approaches can be considered of high interest in this respect. The present review covers 20 years of research on the design of prodrugs for the treatment of neglected and extremely neglected diseases such as Chagas' disease (American trypanosomiasis), sleeping sickness (African trypanosomiasis), malaria, sickle cell disease, tuberculosis, leishmaniasis and schistosomiasis.
Collapse
Affiliation(s)
- Man Chin Chung
- Lapdesf - Laboratório de Desenvolvimento de Fármacos, Departamento de Fármacos e Medicamentos, Faculdade de Ciências Farmacêuticas - UNESP Rodovia Araraquara-Jaú Km 1, 14801-902, Brazil
| | - Elizabeth Igne Ferreira
- LAPEN – Laboratório de Planejamento e Síntese de Quimioterápicos Potencialmente Ativos em Endemias Tropicais, Departamento de Farmácia, Faculdade de Ciências Farmacêuticas – USP/SP, R. Prof. Lineu Prestes, 580, B-13S, Cidade Universitária, São Paulo, 05508-900, Brazil; E-mail:
| | - Jean Leandro Santos
- Lapdesf - Laboratório de Desenvolvimento de Fármacos, Departamento de Fármacos e Medicamentos, Faculdade de Ciências Farmacêuticas - UNESP Rodovia Araraquara-Jaú Km 1, 14801-902, Brazil
- LAPEN – Laboratório de Planejamento e Síntese de Quimioterápicos Potencialmente Ativos em Endemias Tropicais, Departamento de Farmácia, Faculdade de Ciências Farmacêuticas – USP/SP, R. Prof. Lineu Prestes, 580, B-13S, Cidade Universitária, São Paulo, 05508-900, Brazil; E-mail:
| | - Jeanine Giarolla
- LAPEN – Laboratório de Planejamento e Síntese de Quimioterápicos Potencialmente Ativos em Endemias Tropicais, Departamento de Farmácia, Faculdade de Ciências Farmacêuticas – USP/SP, R. Prof. Lineu Prestes, 580, B-13S, Cidade Universitária, São Paulo, 05508-900, Brazil; E-mail:
| | - Daniela Gonçales Rando
- LAPEN – Laboratório de Planejamento e Síntese de Quimioterápicos Potencialmente Ativos em Endemias Tropicais, Departamento de Farmácia, Faculdade de Ciências Farmacêuticas – USP/SP, R. Prof. Lineu Prestes, 580, B-13S, Cidade Universitária, São Paulo, 05508-900, Brazil; E-mail:
| | - Adélia Emília Almeida
- Lapdesf - Laboratório de Desenvolvimento de Fármacos, Departamento de Fármacos e Medicamentos, Faculdade de Ciências Farmacêuticas - UNESP Rodovia Araraquara-Jaú Km 1, 14801-902, Brazil
| | - Priscila Longhin Bosquesi
- Lapdesf - Laboratório de Desenvolvimento de Fármacos, Departamento de Fármacos e Medicamentos, Faculdade de Ciências Farmacêuticas - UNESP Rodovia Araraquara-Jaú Km 1, 14801-902, Brazil
| | - Renato Farina Menegon
- Lapdesf - Laboratório de Desenvolvimento de Fármacos, Departamento de Fármacos e Medicamentos, Faculdade de Ciências Farmacêuticas - UNESP Rodovia Araraquara-Jaú Km 1, 14801-902, Brazil
| | - Lorena Blau
- Lapdesf - Laboratório de Desenvolvimento de Fármacos, Departamento de Fármacos e Medicamentos, Faculdade de Ciências Farmacêuticas - UNESP Rodovia Araraquara-Jaú Km 1, 14801-902, Brazil
| |
Collapse
|